Reimbursement landscape

What is the reimbursement landscape?

The reimbursement landscape is the set of processes, rules and payer requirements that determines whether and how a therapy is funded through public or private healthcare systems. It includes pricing regulation, health technology assessment, coverage criteria, reimbursement pathways and negotiation frameworks.

The landscape differs by geography, payer, care setting, therapeutic area and patient population. A product may receive regulatory approval but still face restricted coverage, price negotiation, evidence requirements or local funding decisions before patients can access it.

Why does the reimbursement landscape matter in market access?

Understanding the landscape allows market access teams to design pricing, evidence and engagement plans around the decisions that payers will actually make. It helps teams identify access barriers, prioritise submissions, anticipate evidence gaps and prepare for negotiations.

This work can affect launch sequencing, indication strategy and the feasibility of achieving broad rather than restricted access. Early analysis also helps clinical, medical, HEOR and commercial teams align their plans with payer expectations instead of addressing reimbursement requirements after the evidence package has been finalised.

How is a reimbursement landscape assessed in practice?

• Define the product, indication, target population, care pathway and likely place in therapy.
• Identify the national, regional and local bodies involved in assessment, pricing, funding and implementation.
• Map relevant reimbursement routes, submission requirements, decision criteria, timelines and opportunities for negotiation or appeal.
• Review comparator products, previous assessments, coverage restrictions, contracting approaches and evidence expectations.
• Test assumptions with local affiliates, payer experts and appropriate external stakeholders.
• Record uncertainties, expected policy changes and implications for evidence generation, price and launch sequence.

The output is usually a structured comparison across priority markets rather than a static description of policy. It should distinguish confirmed requirements from interpretation and show what each finding means for product strategy.

Why can the reimbursement landscape differ between markets and indications?

Healthcare systems allocate budgets and assess value in different ways. Some rely heavily on a central assessment, while others combine national decisions with regional or institutional funding. The relevant comparator, accepted endpoints, economic methods, negotiation process and ability to restrict use may also vary.

Differences can exist within the same market. A medicine used in hospital may follow a different route from one prescribed in the community, and a new indication may face different comparators or coverage criteria from the original indication. Teams should therefore avoid treating a global summary as a substitute for local analysis.

Who owns reimbursement landscape work, and where do teams go wrong?

Ownership commonly sits with global or affiliate market access, with input from HEOR, pricing, medical, regulatory, commercial and policy colleagues. Responsibilities should be clear: local teams validate current practice, while global teams establish a consistent framework and connect findings to evidence and strategy. Relevant insights may feed into a global value dossier, but the landscape itself should remain tailored to each decision context.

Common errors include relying on outdated rules, focusing only on formal national processes, assuming regulatory approval leads to funding, and describing requirements without stating their strategic consequence. Another mistake is copying competitor outcomes without considering differences in indication, evidence, comparator, timing or negotiating position.

How does the reimbursement landscape differ from related market access terms?

The reimbursement landscape describes the external environment in which funding decisions are made. Pricing and reimbursement refers more directly to the activities and decisions used to establish a product’s price, coverage and payment conditions within that environment.

HTA is one component of the landscape, not the whole landscape. Market access is broader still, covering the strategy and actions required to secure and maintain patient access. A useful landscape assessment connects these adjacent concepts by showing who decides, what evidence they require, which process applies and what that means for the product.